David Lewis joins Ablatus as CEO

We are delighted to announce the appointment of David Lewis as CEO at Ablatus Therapeutics Ltd. 

David has a strong history of delivery within the global medical technology space, having started his career with Johnson & Johnson and CR Bard. David then spent 15 years at Medtronic, holding progressive Senior Leadership roles, which culminated in heading up the Cardiovascular Group of businesses across the Asia Pacific region. More recently, he was VP International at Endologix Inc. and has also spent several years consulting to early-stage companies, including Veryan Medical, leading on establishing market presence and new product launches across international geographies. 

David has operated as a commercial leader at the most senior level in these market-leading companies, and he joins Ablatus at a particularly exciting time, following the recent award of a significant £1.42 m Innovate UK grant, and with the company enjoying strong investor support for its pathway to CE mark and commercial availability of the first BETA liver tumour ablation system. 

David is married with 3 children and is based in Leamington Spa, Warwickshire. 

The Board is thrilled to have an executive of David’s experience and calibre take the leadership reins, and we very much look forward to seeing his impact during the coming months.